Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (NYSE: BDX) is a global leader in medical technology driving advancements in healthcare through innovative devices, diagnostic solutions, and clinical systems. This page provides real-time updates on BD's latest developments, offering investors and professionals a centralized hub for tracking corporate announcements and industry impact.
Access authoritative information including earnings reports, regulatory milestones, product innovations, and strategic partnerships. Our curated news collection helps stakeholders monitor BD's contributions to medication management, diagnostic testing, and surgical care across 190+ countries.
Key updates cover BD Medical safety-engineered products, BD Life Sciences diagnostic platforms, and BD Interventional surgical technologies. Stay informed about developments in smart medication systems, infectious disease testing, and minimally invasive procedures shaping modern healthcare.
Bookmark this page for ongoing insights into BD's operational updates, leadership changes, and R&D breakthroughs. Verify critical information directly through primary sources while maintaining awareness of market trends in the $600B+ medical technology sector.
BD (Becton, Dickinson and Company) (NYSE: BDX), a key player in global medical technology, announced its participation in two upcoming virtual healthcare conferences. The Stifel 2020 Virtual Healthcare Conference is scheduled for November 16, 2020, at 9:20 a.m. EDT, followed by the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 7:55 a.m. EDT. Investors can access live webcasts on the corporate website, with recordings available for at least seven days post-conference.
BD (Becton, Dickinson and Company) reported Q4 2020 revenues of $4.784 billion, a 4.4% increase year-over-year. Despite strong contributions from COVID-19 diagnostics, diluted EPS fell to $0.36, down 20%. The BD Medical segment saw a 4.9% revenue decline, while the Life Sciences segment grew 31.2% due to strong diagnostic sales. The company expects fiscal 2021 revenue growth of high single to low double-digits and adjusted EPS between $12.40 and $12.60, reflecting growth over fiscal 2020.
BD (NYSE: BDX) announced key executive appointments effective January 1, 2021. Patrick Kaltenbach is named executive vice president and chief technology officer, succeeding John DeFord, who will retire. Kaltenbach, with nearly 30 years of R&D management experience, will drive BD's innovation strategy and oversee the 'Innovation and Growth Fund.' Additionally, Dave Hickey is promoted to executive vice president and president of the Life Sciences segment, succeeding Kaltenbach. Both leaders will report to CEO Tom Polen, focusing on enhancing BD's impact in medical technology.
CerTest Biotec and BD (Becton, Dickinson and Company) announced that their VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR Detection Kit for the BD MAX™ System has received CE marking under the IVD Directive (98/79/EC). This kit enables simultaneous testing for COVID-19, Influenza, and RSV, enhancing diagnostic capabilities during flu season. The BD MAX™ System is already used in numerous European laboratories, providing rapid results within two to three hours. BD's collaboration with CerTest aims to improve diagnostic efficiency and patient care during the winter season.
BD (Becton, Dickinson and Company) celebrates 25 years of partnership with Mercy Ships, announcing a donation of $1 million to support the launch of the Global Mercy, the world's largest NGO hospital ship. This contribution increases BD's total philanthropic investment in Mercy Ships to $2.5 million. The ship, set to sail to Africa in late 2021, features advanced medical facilities and aims to address the severe lack of surgical care, particularly in Africa, where 93% of the 18.6 million annual deaths due to inadequate surgical access occur.
BD (Becton, Dickinson and Company) has received 510(k) clearance from the U.S. FDA for its FACSLyric™ Flow Cytometer combined with the BD FACSDuet™ Sample Preparation System. This integrated system fully automates the sample-to-answer process, enhancing laboratory efficiency by reducing errors and minimizing manual interventions. The FACSDuet provides a walkaway solution that streamlines workflows and improves data integration with laboratory systems. The system is now available as an IVD system in the U.S. and countries recognizing CE-IVD certification.
BD (Becton, Dickinson and Company) announced a live webcast for its fourth fiscal quarter and full fiscal year 2020 earnings conference call on November 5, 2020, at 8:00 a.m. (ET). The earnings press release will precede the call. Investors can access the webcast and related slides on the company's investor website, with a replay available until November 12, 2020. BD operates globally, focusing on advancing health through innovative medical technologies, enhancing care delivery, and supporting health care providers.
BD (Becton, Dickinson and Company) has announced that its SARS-CoV-2 antigen test for the BD Veritor™ Plus System has received CE marking, allowing for commercial availability in Europe by the end of October. This rapid test provides results in just 15 minutes, enhancing COVID-19 diagnostic turnaround times. BD plans to produce 8 million tests per month by October and 12 million by March 2021. The system, already in use for other respiratory conditions, allows simultaneous testing for SARS-CoV-2 and influenza A+B, addressing critical healthcare needs during flu season.
On September 23, 2020, BD (Becton, Dickinson and Company) submitted a PMA supplement to the FDA for the ThinPrep® Pap Test™ PreservCyt® Solution vial as an approved sample type for its BD Onclarity™ HPV Assay. This submission aims to expand sample claims beyond the BD SurePath™ vial, providing crucial performance data for BD Viper™ LT and BD COR™ Systems. The company recently received FDA approval for extended genotype reporting, enhancing the assay's capabilities. This commitment underscores BD's focus on improving cervical cancer screening and patient management.
BD (Becton, Dickinson and Company) has updated the status of its voluntary recalls of the BD Alaris™ System, initiated on August 4, 2020. The FDA classified three recalls as Class I, indicating a significant risk of serious health consequences or death, while one was classified as Class II. The recalls address issues such as unresponsive keypad keys and incorrect module sizes for infusion pumps, potentially leading to delays or inaccuracies in medication delivery. Customers are advised to follow recall instructions provided by BD.